Gongyan Chen

机构：Harbin Medical University, Chinese Academy of Medical Sciences & Peking Union Medical College, Third Affiliated Hospital of Harbin Medical University

发表论文 29 篇 · 总被引 1045 次 · h-index 14

代表论文

• Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12) (2021 · Journal of Thoracic Oncology · 被引 324)
• Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study (2022 · The Lancet Respiratory Medicine · 被引 236)
• Central Nervous System Efficacy of Furmonertinib (AST2818) Versus Gefitinib as First-Line Treatment for EGFR-Mutated NSCLC: Results From the FURLONG Study (2022 · Journal of Thoracic Oncology · 被引 79)
• MCM2 is a therapeutic target of lovastatin in human non-small cell lung carcinomas (2015 · Oncology Reports · 被引 65)
• Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer (2024 · JAMA Oncology · 被引 63)
• First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial (2024 · The Lancet Respiratory Medicine · 被引 59)